



## **Codiak BioSciences to Participate at William Blair Biotech Focus Conference 2022**

July 11, 2022

CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be attending the William Blair Biotech Focus Conference 2022 in New York City. Codiak's Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a panel discussion entitled "*Developing Therapies for the Next Immuno-Oncology Targets*," on Tuesday, July 12 from 4:10 - 5:20 pm ET and the Company will also be hosting one-on-one meetings at the conference.

### **About Codiak BioSciences**

Codiak is a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx<sup>®</sup> Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, infectious disease and rare disease. For more information, please visit [www.codiakbio.com](http://www.codiakbio.com).

### **Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements concerning the clinical development and therapeutic potential of exoSTING and exoIL-12. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Codiak's Annual Report on Form 10-K for the year ended December 31, 2021, and in subsequent filings with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in Codiak's subsequent filings with the Securities and Exchange Commission. All information in this press release is current as of the date of this report, and Codiak undertakes no duty to update this information unless required by law.

### **Investor Contact:**

Christopher Taylor  
VP, Investor Relations and Corporate Communications  
T: 617-949-4220  
E: [investor@codiakbio.com](mailto:investor@codiakbio.com)

### **Media Contact:**

Cory Tromblee  
Scient PR  
[media@codiakbio.com](mailto:media@codiakbio.com)